DRTS Latest Press Releases

-- October 22, 2026 --

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT for Pancreatic Cancer Patients in Korea Globe Newswire 8:30 AM

-- October 19, 2026 --

Alpha Tau Announces FDA Approval to Expand Alpha DaRT U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting Globe Newswire 8:30 AM

-- October 5, 2026 --

Alpha Tau to Participate in October Investor Conferences Globe Newswire 9:45 AM

-- September 2, 2026 --

Alpha Tau to Participate in September Investor Conferences Globe Newswire 8:00 AM

-- August 31, 2026 --

Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT Following Strong Demand and Multiple Expansions Globe Newswire 8:00 AM

-- August 17, 2026 --

Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee Globe Newswire 8:00 AM

-- August 10, 2026 --

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE) Globe Newswire 8:00 AM

-- July 21, 2026 --

Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success Globe Newswire 8:30 AM

-- July 15, 2026 --

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center Globe Newswire 8:30 AM

-- June 25, 2026 --

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet PRNewswire 11:35 AM

-- June 23, 2026 --

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT at Hadassah University Medical Center in Israel Globe Newswire 8:30 AM

-- June 11, 2026 --

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control Globe Newswire 8:30 AM

-- June 3, 2026 --

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT Therapy to U.S. Urological Cancer Patients Globe Newswire 8:30 AM

-- June 1, 2026 --

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting Globe Newswire 9:00 AM

Market Data Delayed 15 Minutes